Source link : https://www.newshealth.biz/health-news/win-for-perioperative-durvalumab-in-muscle-invasive-bladder-cancer/
Adding perioperative durvalumab (Imfinzi) to neoadjuvant chemotherapy significantly improved survival outcomes in cisplatin-eligible patients with muscle-invasive bladder cancer (MIBC), a phase III trial showed. Estimated 24-month event-free survival (EFS) rates reached 67.8% in the durvalumab group and 59.8% in the neoadjuvant chemotherapy-alone group (HR 0.68, 95% CI 0.56-0.82, P
Author : News Health
Publish date : 2024-09-16 18:34:32
Copyright for syndicated content belongs to the linked Source.